This trial is testing the drug PT-112 to see if it can help people with thymoma or thymic cancer whose disease returned or progressed after treatment with at least one platinum-containing chemotherapy.
- Thymic Epithelial Tumors
- Recurrent Thymoma
- Thymic Cancer
1 Primary · 5 Secondary · Reporting Duration: assessed every 8 weeks while on treatment and then every 3 months after that for a maximum of 8 years from the start of study
1 Treatment Group
1 of 1
53 Total Participants · 1 Treatment Group
Primary Treatment: PT-112 · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
When might we see PT-112 on the market?
"PT-112 falls into Phase 2 of clinical trials, meaning that while there is safety data, there is none yet supporting efficacy." - Anonymous Online Contributor
Can people with the required qualifications sign up for this clinical trial right now?
"This study, which is currently looking for participants, was first posted on April 6th, 2022. The most recent update to the trial was on October 13th, 2022." - Anonymous Online Contributor
How many people can sign up for this research project?
"That is correct. The clinicaltrials.gov website currently has information indicating that this trial is seeking participants. This study was originally posted on April 6th, 2022 and updated on October 13th, 2022. They are looking for 53 people to participate at 1 location." - Anonymous Online Contributor